Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.

Withdrawal due to adverse events higher with nalmefene

02 Sep 2017

Patients receiving nalmefene to treat impulse control disorders or substance use suffer from a threefold greater risk of withdrawal because of adverse safety events, according to a new meta-analysis.

The meta-analysis included eight randomized controlled trials (RCTs), of which only six reported serious adverse events (SAEs). There was no significant difference in SAE between the nalmefene and placebo groups (Peto odds ratio [POR], 0.97; 95 percent CI, 0.64 to 1.44; p=0.86; risk difference [RD], -0.00; -0.02 to -0.01; p=0.84).

Similarly, the odds for overall psychiatric SAEs were not significantly different between the nalmefene and placebo groups (POR, 1.32; 0.62 to 2.38; p=0.47; RD, 0.00; -0.01 to 0.01; p=0.40). There were also no differences in the risk of depression, anxiety or death.

Pooled findings from all eight RCTs showed that withdrawals due to adverse events were significantly higher in the nalmefene group than in the placebo group (POR, 3.22; 2.46 to 4.22; p<0.00; RD, 0.09; 0.08 to 0.11; p=0.00).

RCTs were included in the meta-analysis if they compared nalmefene to placebo or active controls in patients with impulse control and/or substance use disorders. Those with data on harms were included.

The databases of PubMed, Medline, Embase, Clinicaltrials.gov and the Cochrane Central Register of Controlled Trials were accessed.

Fifteen studies fulfilled the eligibility criteria and only eight were included in the final analysis because of missing harms data. Of the 15 studies, two were still ongoing. The remaining 13 studies corresponded to 3,793 participants.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.